Health and Medical Research in Australia II: A Golden Egg Opportunity Too Valuable to Underfund [0.03%]
澳大利亚卫生和医学研究II：一个不愿低估的宝贵机会
Levon M Khachigian
Levon M Khachigian
Artificial protein scaffolds for human therapeutics: drug discovery and delivery strategies [0.03%]
用于人类治疗的蛋白质支架：药物发现与传递策略
Amol D Gholap,Pankaj Khuspe,Abdelwahab Omri
Amol D Gholap
Artificial protein scaffolds have emerged as next-generation biologics that address key limitations of monoclonal antibodies, including large size, poor tissue penetration and complex manufacturing. This review discusses major scaffold clas...
Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator [0.03%]
药物发现联盟的建立和管理：结核病药物加速器计划的启示
Kelsey L Briggs,Betsy J Russell,Peter Warner et al.
Kelsey L Briggs et al.
Developing tuberculosis drug regimens requires coordinated discovery of multiple, mechanistically distinct agents, which challenge traditional single-asset models. The Tuberculosis Drug Accelerator (TBDA) was established as a multi-organiza...
Integrating AI-enhanced kinase enrichment analysis (KEA) with geometric deep learning and federated learning for precision drug repurposing [0.03%]
基于几何深度学习和联邦学习的AI增强型激酶富集分析（KEA）在精准药物重定位中的应用集成研究
Saleem Iqbal,Jing Chen,Debnath Pal et al.
Saleem Iqbal et al.
Artificial intelligence (AI) is reshaping drug repurposing by integrating systems biology with molecular design. Here, we present a unified framework combining AI-enhanced Kinase Enrichment Analysis (KEA), geometric deep learning, and feder...
A statewide multi-institutional model that de-risks academic drug discovery [0.03%]
一种州范围的多机构模型可降低学术药物发现风险
Suzanne Tomlinson-Mathis;IDDD Core Network
Suzanne Tomlinson-Mathis;IDDD Core Network
Texas has built a coordinated, multi-institution core network that de-risks academic discoveries while reducing redundant rebuilds across institutions. Through a distributed drug R&D model, autonomous cores collaborate via shared forums and...
Xian-Ming Tao,Peng Liu,Peng Zhao et al.
Xian-Ming Tao et al.
Cardiac fibrosis is a pathological process characterized by excessive collagen deposition and abnormal proliferation of cardiac fibroblasts. This condition can lead to impaired cardiac function and ventricular remodeling. The development of...
The host-steroid-microbiome axis: Microbial remodeling of steroid scaffolds and its implications for metabolic and endocrine disorders [0.03%]
宿主-类固醇-微生物组轴系：微生物对类固醇支架的重塑及其在代谢和内分泌紊乱中的影响
Thanga Y Gajendiran,Nila Ganamurali,Sarvesh Sabarathinam
Thanga Y Gajendiran
Steroids, chemically conserved yet functionally diverse, integrate metabolic, endocrine and microbial networks. Beyond host hormones acting via specific receptors, the gut microbiome edits steroid scaffolds, yielding metabolites that reshap...
Ailin Deng,Wenzhi Jia,Gang Huang et al.
Ailin Deng et al.
Trop2 (Trophoblast cell surface antigen 2) is a crucial tumor-associated antigen that is overexpressed in various epithelial-derived cancers. Thus, it has become a key target for molecular imaging and therapy. Immuno-positron emission tomog...
Integrating in vitro and in silico NAMs for enhanced prediction of drug-induced liver injury [0.03%]
体外和体内的集成模型在预测药物引起的肝损伤中的应用
Ting Li,Shivangi Shrimali,Yanyan Qu et al.
Ting Li et al.
Regulatory efforts to reduce animal testing have accelerated the adoption of new approach methodologies (NAMs). We present an integrated framework combining a published in silico model (DeepDILI) with six independent human liver spheroid as...
Regulatory innovation for drug repurposing: Ten proposals to accelerate access and safety [0.03%]
促进药物再利用的监管创新——加速准入和保障安全的十项建议
Sara Pintado,Adelaide Fernandes,Esther A M Bührman et al.
Sara Pintado et al.
Despite increasing efforts and incentives to address the critical lack of treatments for rare diseases, a substantial gap persists between patient needs and available therapies. Drug repurposing is a promising strategy in this field; nevert...